Company intelligence / Profile preview
Suzhou Maximum Bio-tech
Suzhou, Jiangsu, Chinalinkedin.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AMT-253 ADC: Preclinical studies show a wide therapeutic window; currently in first-in-human Phase I trial for MUC18-positive solid tumors with ongoing recruitment. Other pipeline assets are in early-phase trials or preclinical development.
- Therapeutic areas
- HematologyImmunologyOncology
- Modalities
- Antibody-drug conjugateCAR-T cell therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
GenScript Biotech
Beyond the preview
Go deeper on Suzhou Maximum Bio-tech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Maximum Bio-tech.